Respiratory
Pipeline

Lungs

About our Respiratory Diseases efforts

We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung diseases. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of innovative therapies for patients with a broad range of lung diseases who have a high unmet medical need.

Read more about Nerandomilast (BI 1015550): PDE4B inhibitor

Respiratory

Idiopathic pulmonary fibrosis

PDE4B inhibitor

Nerandomilast (BI 1015550)

Read more about Nerandomilast (BI 1015550): PDE4B inhibitor

Respiratory

Progressive pulmonary fibrosis

PDE4B inhibitor

Nerandomilast (BI 1015550)

Read more about BI 1291583: CatC Inhibitor

Respiratory

Non-cystic fibrosis bronchiectasis

CatC inhibitor

BI 1291583

Read more about Lysophospholipase inhibitor

Respiratory

Idiopathic/progressive pulmonary fibrosis

Lysophospholipase inhibitor

BI 1819479

Read more about IL11 antibody

Respiratory

IL11 antibody

Read more about Ion channel inhibitor

Respiratory

Ion channel inhibitor

Read more about Oxidase Inhibitor

Respiratory

Oxidase Inhibitor